Beyond COVID - The Case for Infectious Disease Drug Discovery

Recorded live June 3, 2021

As the world gradually recovers from the recent viral pandemic, it is important to remember that there are numerous other serious infectious diseases that affect millions of lives across continents. In this webinar, University of Washington professors Frederick Buckner and Michael Gelb shared their insights in basic and applied research to address such diseases including leishmaniasis, malaria, and Chagas disease.

Featuring these leading scientists...

Frederick S. Buckner, M.D.

Professor, Department of Medicine, University of Washington

A physician by training, Frederick Buckner's research concentrates on drug discovery for diseases caused by pathogenic protozoa. The lab focuses mainly on several biochemical targets for developing anti-parasitic drugs including sterol biosynthesis, protein prenylation, protein synthesis, and protein kinases. 

Dr. Buckner received his M.D. degree from University of Washington School of Medicine, followed by a residency at University of Minnesota.

Michael H. Gelb, Ph.D.

Professor of Chemistry, University of Washington

Michael Gelb is the Boris and Barbara L. Weinstein Endowed Chair in Chemistry in the Department of Chemistry. The Gelb group combines chemical and molecular and cellular biochemistry techniques to study enzymatic processes of medical importance, with applications in the development of drugs to treat parasitic diseases.

Dr. Gelb obtained his undergraduate degree from the University of California at Davis, and his Ph.D. degree from Yale University.